Anti-Alzheimer therapeutic drugs targeting γ-secretase

Current Topics in Medicinal Chemistry

Volumn 16, Issue 5, 2016, Pages 549-557

  Tan, Yan ^a   Zhang, Qi ^a   Wong, Steven G ^a   Hua, Qian ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Alzheimer disease; Natural products; Presenilin; secretase inhibitors; secretase modulators

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AVAGACESTAT; BEGACESTAT; CIMICIFUGA RACEMOSA EXTRACT; CURCUMIN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE MODULATOR; GARCINIELLIPTONE HC; GINSENOSIDE RG 3; MK 0752; PRESENILIN; SEMAGACESTAT; TARENFLURBIL; UNCLASSIFIED DRUG; ENZYME INHIBITOR; SECRETASE;

ACTAEA RACEMOSA; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CHINESE MEDICINE; CLINICAL TRIAL (TOPIC); CURCUMA LONGA; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GINSENG; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; METABOLISM;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ENZYME INHIBITORS; HUMANS;

EID: 84973431448     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150813144151     Document Type: Article

References (76)

1. Berchtold, N.C.; Cotman, C.W. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol. Aging, 1998, 19(3), 173-189.
2. Association, A.S. Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, J. Alzheimer’s Assoc., 2015, 11(3), 332-384.
3. Chuan-Feng, C.; Cheng-Lin, H.; Hong-Xia, C.; Ya-Fei, S.; Xin P. A Summary of Dementia Studies in China. J. Ningbo. Univ. (Edu Sci Ed, 2012, 34(2), 45-50.
4. Bartlett, P.F.; He R. Introduction to the thematic issue "From brain function to therapy". Sci. China Life Sci., 2014, 57(4), 363-365.
5. Panza, F.; Frisardi, V.; Imbimbo, B.P.; Capurso, C.; Logroscino, G.; Sancarlo, D.; Seripa, D.; Vendemiale, G.; Pilotto, A.; Solfrizzi, V. REVIEW: gamma-Secretase inhibitors for the treatment of Alzheimer’s disease: The current state. CNS Neurosci. Ther., 2010, 16(5), 272-284.
6. Nguyen, T.H.; Qiu, X.; Sun, J.; Meunier, F.A. Bulk endocytosis at neuronal synapses. Sci. China Life Sci., 2014, 57(4), 378-383.
7. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400(6740), 173-177.
8. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64(9), 1553-1562.
9. Fleisher, A.S.; Raman, R.; Siemers, E.R.; Becerra, L.; Clark, C.M.; Dean, R.A.; Farlow, M.R.; Galvin, J.E.; Peskind, E.R.; Quinn, J.F.; Sherzai, A.; Sowell, B.B.; Aisen, P.S.; Thal, L.J. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Archives Neurol., 2008, 65(8), 1031-1038.
10. Siemers, E.; Skinner, M.; Dean, R.A.; Gonzales, C.; Satterwhite, J.; Farlow, M.; Ness, D.; May, P.C. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gammasecretase inhibitor in volunteers. Clin. Neuropharmacol., 2005, 28(3), 126-132.
11. Doody, R.S.; Raman, R.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; He, F.; Sun, X.; Thomas, R.G.; Aisen, P.S.; Siemers, E.; Sethuraman, G.; Mohs, R. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. New Engl. J. Med., 2013, 369(4), 341-350.
12. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer’s disease, follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372(9634), 216-223.
13. Qian H, Hai-Min D, Mi L. Progress on Aβ-Targeted Therapeutic Strategies for Alzheimer’s Disease. Prog. Biochem. Biophys., 2012, 39(8), 734-740.
14. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease, progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356.
15. Castellani, R.J.; Lee, H.G.; Siedlak, S.L.; Nunomura, A.; Hayashi, T.; Nakamura, M.; Zhu, X.; Perry, G.; Smith, M.A. Reexamining Alzheimer’s disease, evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J. Alzheimer’s Dis., 2009, 18(2), 447-452.
16. Puzzo, D.; Privitera, L.; Leznik, E.; Fa, M.; Staniszewski, A.; Palmeri, A.; Arancio, O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci., 2008, 28(53), 14537-14545.
17. Morley, J.E.; Farr, S.A.; Banks, W.A.; Johnson, S.N.; Yamada, K.A.; Xu, L. A physiological role for amyloid-beta protein, enhancement of learning and memory. J. Alzheimer’s Dis., 2010, 19(2), 441-449.
18. Guardia-Laguarta, C.; Pera, M.; Lleo, A. gamma-Secretase as a therapeutic target in Alzheimer’s disease. Curr. Drug Targets, 2010, 11(4), 506-517.
19. Haapasalo, A.; Kovacs, D.M. The many substrates of presenilin/ gamma-secretase. J. Alzheimer’s Dis., 2011, 25(1), 3-28.
20. Haass, C.; Selkoe, D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell, 1993, 75(6), 1039-1042.
21. Schroeter, E.H.; Kisslinger, J.A.; Kopan, R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature, 1998, 393(6683), 382-386.
22. Artavanis-Tsakonas, S.; Matsuno, K.; Fortini, M.E. Notch signaling. Science, 1995, 268(5208), 225-232.
23. Nakayama, K.; Nagase, H.; Hiratochi, M.; Koh, C.S.; Ohkawara, T. Similar mechanisms regulated by gamma-secretase are involved in both directions of the bi-directional Notch-Delta signaling pathway as well as play a potential role in signaling events involving type 1 transmembrane proteins. Curr. Stem Cell Res. Therapy, 2008, 3(4), 288-302.
24. Bolos, V.; Grego-Bessa, J.; De La Pompa, J.L. Notch signaling in development and cancer. Endocrine Rev., 2007, 28(3), 339-363.
25. Shen, J.; Bronson, R.T.; Chen, D.F.; Xia, W.; Selkoe, D.J.; Tonegawa, S. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell, 1997, 89(4), 629-639.
26. Handler, M.; Yang, X.; Shen, J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development, 2000, 127(12), 2593-2606.
27. Wolfe, M.S.; Citron, M.; Diehl, T.S.; Xia, W.; Donkor, I.O.; Selkoe, D.J. A substrate-based difluoro ketone selectively inhibits Alzheimer’s gamma-secretase activity. J. Med. Chem., 1998, 41(1), 6-9.
28. Li, Y.M.; Xu, M.; Lai, M.T.; Huang, Q.; Castro, J.L.; Dimuzio- Mower, J.; Harrison, T.; Lellis, C.; Nadin, A.; Neduvelil, J.G.; Register, R.B.; Sardana, M.K.; Shearman, M.S.; Smith, A.L.; Shi, X.P.; Yin, K.C.; Shafer, J.A.; Gardell, S.J. Photoactivated gammasecretase inhibitors directed to the active site covalently label presenilin 1. Nature, 2000, 405(6787), 689-694.
29. Seiffert, D.; Bradley, J.D.; Rominger, C.M.; Rominger, D.H.; Yang, F.; Meredith, J.E. Jr.; Wang, Q.; Roach, A.H.; Thompson, L.A.; Spitz, S.M.; Higaki, J.N.; Prakash, S.R.; Combs, A.P.; Copeland, R.A.; Arneric, S.P.; Hartig, P.R.; Robertson, D.W.; Cordell, B.; Stern, A.M.; Olson, R.E.; Zaczek, R. Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J. Biol. Chem., 2000, 275(44), 34086-34091.
30. Golde, T.E.; Koo, E.H.; Felsenstein, K.M.; Osborne, B.A.; Miele, L. gamma-Secretase inhibitors and modulators. Biochim. et Biophys. Acta, 2013, 1828(12), 2898-2907.
31. Olson, R.E.; Albright, C.F. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr. Top. Med, Chem., 2008, 8(1), 17-33.
32. Bateman, R.J.; Siemers, E.R.; Mawuenyega, K.G.; Wen, G.; Browning, K.R.; Sigurdson, W.C.; Yarasheski, K.E.; Friedrich, S.W.; Demattos, R.B.; May, P.C.; Paul, S.M.; Holtzman, D.M. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol., 2009, 66(1), 48-54.
33. Gitter, B.D.; Dan, L.C.; Li, W.; Dieckman, D.K.; Bender, M.H.; Nissen, J.S.; Mabry, T.E.; Yin, T.; Boggs, L.N.; Mcclure, D.B. P4- 339 Stereoselective inhibition of amyloid beta peptide secretion by LY450139, a novel functional gamma secretase inhibitor. Neurobiol. Aging, 2004, 25(4), 65-71.
34. Siemers, E.R.; Dean, R.A.; Friedrich, S.; Ferguson-Sells, L.; Gonzales, C.; Farlow, M.R.; May, P.C. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin. Neuropharmacol., 2007, 30(6), 317-325.
35. Searfoss, G.H.; Jordan, W.H.; Calligaro, D.O.; Galbreath, E.J.; Schirtzinger, L.M.; Berridge, B.R.; Gao, H.; Higgins, M.A.; May, P.C.; Ryan, T.P.; Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J. Biol. Chem., 2003, 278(46), 46107-46116.
36. Henley, D.B.; Sundell, K.L.; Sethuraman, G.; Dowsett, S.A.; May, P.C. Safety profile of semagacestat, a gamma-secretase inhibitor, IDENTITY trial findings. Curr. Med. Res. Opin., 2014, 30(10), 2021-2032.
37. Fuwa, H.; Hiromoto, K.; Takahashi, Y.; Yokoshima, S.; Kan, T.; Fukuyama, T.; Iwatsubo, T.; Tomita, T.; Natsugari, H. Synthesis of biotinylated photoaffinity probes based on arylsulfonamide gamma-secretase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(16), 4184-4189.
38. Tong, G.; Wang, J.S.; Sverdlov, O.; Huang, S.P.; Slemmon, R.; Croop, R.; Castaneda, L.; Gu, H.; Wong, O.; Li, H.; Berman, R.M.; Smith, C.; Albright, C.F.; Dockens, R.C. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat), tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clin. Ther., 2012, 34(3), 654-667.
39. Tong, G.; Wang, J.S.; Sverdlov, O.; Huang, S.P.; Slemmon, R.; Croop, R.; Castaneda, L.; Gu, H.; Wong, O.; Li, H.; Berman, R.M.; Smith, C.; Albright, C.F.; Dockens, R. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the gamma-secretase inhibitor avagacestat. Br. J. Clin. Pharmacol., 2013, 75(1), 136-145.
40. Gillman, K.W.; Starrett, J.E. Jr.; Parker, M.F.; Xie, K.; Bronson, J.J.; Marcin, L.R.; Mcelhone, K.E.; Bergstrom, C.P.; Mate, R.A.; Williams, R.; Meredith, J.E. Jr.; Burton, C.R.; Barten, D.M.; Toyn, J.H.; Roberts, S.B.; Lentz, K.A.; Houston, J.G.; Zaczek, R.; Albright, C.F.; Decicco, C.P.; Macor, J.E.; Olson, R.E. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable gamma-Secretase Inhibitor. ACS Med. Chem. Lett., 2010, 1(3), 120-124.
41. Coric, V.; Van Dyck, C.H.; Salloway, S.; Andreasen, N.; Brody, M.; Richter, R.W.; Soininen, H.; Thein, S.; Shiovitz, T.; Pilcher, G.; Colby, S.; Rollin, L.; Dockens, R.; Pachai, C.; Portelius, E.; Andreasson, U.; Blennow, K.; Soares, H.; Albright, C.; Feldman, H.H.; Berman, R.M. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch. Neurol., 2012, 69(11), 1430-1440.
42. Martone, R.L.; Zhou, H.; Atchison, K.; Comery, T.; Xu, J.Z.; Huang, X.; Gong, X.; Jin, M.; Kreft, A.; Harrison, B.; Mayer, S.C.; Aschmies, S.; Gonzales, C.; Zaleska, M.M.; Riddell, D.R.; Wagner, E.; Lu, P.; Sun, S.C.; Sonnenberg-Reines, J.; Oganesian, A.; Adkins, K.; Leach, M.W.; Clarke, D.W.; Huryn, D.; Abou-Gharbia, M.; Magolda, R.; Bard, J.; Frick, G.; Raje, S.; Forlow, S.B.; Balliet, C.; Burczynski, M.E.; Reinhart, P.H.; Wan, H.I.; Pangalos, M.N.; Jacobsen, J.S. Begacestat (GSI-953), a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gammasecretase for the treatment of Alzheimer’s disease. J. Pharmacol. Exp. Ther., 2009, 331(2), 598-608.
43. Eriksen, J.L.; Sagi, S.A.; Smith, T.E.; Weggen, S.; Das, P.; Mclendon, D.C.; Ozols, V.V.; Jessing, K.W.; Zavitz, K.H.; Koo, E.H.; Golde, T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest., 2003, 112(3), 440-449.
44. Crump, C.J.; Johnson, D.S.; Li, Y.M. Development and mechanism of gamma-secretase modulators for Alzheimer’s disease. Biochemistry, 2013, 52(19), 3197-3216.
45. Galasko, D.R.; Graff-Radford, N.; May, S.; Hendrix, S.; Cottrell, B.A.; Sagi, S.A.; Mather, G.; Laughlin, M.; Zavitz, K.H.; Swabb, E.; Golde, T.E.; Murphy, M.P.; Koo, E.H. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis. Assoc. Disord., 2007, 21(4), 292-299.
46. Wilcock, G.K.; Black, S.E.; Hendrix, S.B.; Zavitz, K.H.; Swabb, E.A.; Laughlin, M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease, a randomised phase II trial. Lancet Neurol., 2008, 7(6), 483-493.
47. Green, R.C.; Schneider, L.S.; Amato, D.A.; Beelen, A.P.; Wilcock, G.; Swabb, E.A.; Zavitz, K.H. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease, a randomized controlled trial. JAMA, 2009, 302(23), 2557-2564.
48. Gijsen, H.J.; Mercken, M. gamma-Secretase Modulators, Can We Combine Potency with Safety? Int. J. Alzheimer’s Dis., 2012, 2012(295207), 1-10.
49. Xia, W.; Wong, S.T.; Hanlon, E.; Morin, P. gamma-Secretase modulator in Alzheimer’s disease, shifting the end. J. Alzheimer’s Dis., 2012, 31(4), 685-696.
50. Pettersson, M.; Kauffman, G.W.; Am Ende, C.W.; Patel, N.C.; Stiff, C.; Tran, T.P.; Johnson, D.S. Novel gamma-secretase modulators, a review of patents from 2008 to 2010. Expert Opin. Ther. Patents, 2011, 21(2), 205-226.
51. Portelius, E.; Van Broeck, B.; Andreasson, U.; Gustavsson, M.K.; Mercken, M.; Zetterberg, H.; Borghys, H, Blennow K. Acute effect on the Abeta isoform pattern in CSF in response to gammasecretase modulator and inhibitor treatment in dogs. J. Alzheimer’s Dis., 2010, 21(3), 1005-1012.
52. Nagy, C.; Schuck, E.; Ishibashi, A.; Nakatani, Y.; Rege, B.; Logovinsky, V. E2012, a novel gamma-secretase modulator, decreases plasma amyloid-beta (Aβ) levels in humans. Alzheimers Dementia, 2010, 6(4), S574.
53. Nakano-Ito, K.; Fujikawa, Y.; Hihara, T.; Shinjo, H.; Kotani, S.; Suganuma, A.; Aoki, T.; Tsukidate, K. E2012-induced cataract and its predictive biomarkers. Toxicol. Sci., 2014, 137(1), 249-258.
54. Xia, D.; Watanabe, H.; Wu, B.; Lee, S.H.; Li, Y.; Tsvetkov, E.; Bolshakov, V.Y.; Shen, J.; Kelleher, R.J. 3rd. Presenilin-1 knockin mice reveal loss-of-function mechanism for familial Alzheimer’s disease. Neuron, 2015, 85(5), 967-981.
55. Wesnes, K.A.; Ward, T.; Mcginty, A.; Petrini, O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology, 2000, 152(4), 353-361.
56. Reay, J.L.; Kennedy, D.O.; Scholey, A.B. Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mental activity. J. Psychopharmacol., 2005, 19(4), 357-365.
57. Kang, M.S.; Baek, S.H.; Chun, Y.S.; Moore, A.Z.; Landman, N.; Berman, D.; Yang, H.O.; Morishima-Kawashima, M.; Osawa, S.; Funamoto, S.; Ihara, Y.; Di Paolo, G.; Park, J.H.; Chung, S.; Kim, T.W. Modulation of lipid kinase PI4KIIalpha activity and lipid raft association of presenilin 1 underlies gamma-secretase inhibition by ginsenoside (20S)-Rg3. J. Biol. Chem., 2013, 288(29), 20868-20882.
58. Zhang, X.; Wang, J.; Xing, Y.; Gong, L.; Li, H.; Wu, Z.; Li, Y.; Wang, J.; Wang, Y.; Dong, L.; Li, S. Effects of ginsenoside Rg1 or 17beta-estradiol on a cognitively impaired, ovariectomized rat model of Alzheimer’s disease. Neuroscience, 2012, 220(18), 191-200.
59. Quan, Q.; Wang, J.; Li, X.; Wang, Y. Ginsenoside Rg1 decreases Abeta(1-42) level by upregulating PPARgamma and IDE expression in the hippocampus of a rat model of Alzheimer’s disease. PloS one, 2013, 8(3), e59155.
60. Yang, K.; Tan, Y.; Wang, F.; Zhang, Q.; Sun, P.; Zhang, Y.; Yao, N.; Zhao, Y.; Wang, X.; Fan, A.; Hua, Q. The improvement of spatial memory deficits in APP/V717I transgenic mice by chronic antistroke herb treatment. Exp. Biol. Med., 2014, 239(8), 1007-1017.
61. He, P.; Li, P.; Hua, Q.; Liu, Y.; Staufenbiel, M.; Li, R.; Shen, Y. Chronic administration of anti-stroke herbal medicine TongLuoJiuNao reduces amyloidogenic processing of amyloid precursor protein in a mouse model of Alzheimer’s disease. PloS one, 2013, 8(3), e58181.
62. Findeis, M.A.; Schroeder, F.; Mckee, T.D.; Yager, D.; Fraering, P.C.; Creaser, S.P.; Austin, W.F.; Clardy, J.; Wang, R.; Selkoe, D.; Eckman, C.B. Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa. ACS Chem. Neurosci., 2012, 3(11), 941-951.
63. Xiong, Z.; Hongmei, Z.; Lu, S.; Yu, L. Curcumin mediates presenilin- 1 activity to reduce beta-amyloid production in a model of Alzheimer’s Disease. Pharmacol. Rep., 2011, 63(5), 1101-1108.
64. Sasaoka, N.; Sakamoto, M.; Kanemori, S.; Kan, M.; Tsukano, C.; Takemoto, Y.; Kakizuka, A. Long-term oral administration of hop flower extracts mitigates Alzheimer phenotypes in mice. PloS one, 2014, 9(1), e87185.
65. Shen, J.; Kelleher, R.J. 3rd. The presenilin hypothesis of Alzheimer’s disease, evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. USA, 2007, 104(2), 403-409.
66. Bolduc, D.M.; Wolfe, M.S. Structure of nicastrin unveils secrets of gamma-secretase. Proc. Natl. Acad. Sci. USA, 2014, 111(41), 14643-14644.
67. Lee, S.H.; Sharma, M.; Sudhof, T.C.; Shen, J. Synaptic function of nicastrin in hippocampal neurons. Proc. Natl. Acad. Sci. USA, 2014, 111(24), 8973-8978.
68. Xie, T.; Yan, C.; Zhou, R.; Zhao, Y.; Sun, L.; Yang, G.; Lu, P.; Ma, D.; Shi, Y. Crystal structure of the gamma-secretase component nicastrin. Proc. Natl. Acad. Sci. USA, 2014, 111(37), 13349-13354.
69. Lu, P.; Bai, X.C.; Ma, D.; Xie, T.; Yan, C.; Sun, L.; Yang, G.; Zhao, Y.; Zhou, R.; Scheres, S.H.; Shi, Y. Three-dimensional structure of human gamma-secretase. Nature, 2014, 512(7513), 166-170.
70. Sun, L.; Zhao, L.; Yang, G.; Yan, C.; Zhou, R.; Zhou, X.; Xie, T.; Zhao, Y.; Wu, S.; Li, X.; Shi, Y. Structural basis of human gammasecretase assembly. Proc. Natl. Acad. Sci. USA, 2015, 112(19), 6003-6008.
71. Lu, J.; Li, T.; He, R.; Bartlett, P.F.; Gotz, J. Visualizing the microtubule- associated protein tau in the nucleus. Sci. China Life Sci., 2014, 57(4), 422-431.
72. Cramer, P.E.; Cirrito, J.R.; Wesson, D.W.; Lee, C.Y.; Karlo, J.C.; Zinn, A.E.; Casali, B.T.; Restivo, J.L.; Goebel, W.D.; James, M.J.; Brunden, K.R.; Wilson, D.A.; Landreth, G.E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science, 2012, 335(6075), 1503-1506.
73. Zhou, H.; Mangelsdorf, M.; Liu, J.; Zhu, L.; Wu, J.Y. RNAbinding proteins in neurological diseases. Sci. China Life Sci., 2014, 57(4), 432-444.
74. Laura, B.R.; Julie, A.S.; Andrew, P.; Jinyu, Y.; Tim, H.; Mary, F.; Aimee, D.; Catherine, M.; Donna, S.; Dennis, S.; Theresa, P.; Mark, L.; Stanford, J.; Larry, E.; Ronald, S.; Greg, W.; Mark, S.S.; Murphy, M.G.; Keith, M.G. O4-03-02,The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer’s Dementia, 2006, 2, S79–S79.
75. Imbimbo, B.P.; Frigerio, E.; Breda, M.; Fiorentini, F.; Fernandez, M.; Sivilia, S.; Giardino, L.; Calza, L.; Norris, D.; Casula, D.; Shenouda, M. Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Alzheimer Dis. Assoc. Disord., 2013, 27(3), 278-286.
76. Ross, J.; Sharma, S.; Winston, J.; Nunez, M.; Bottini, G.; Franceschi, M.; Scarpini, E.; Frigerio, E.; Fiorentini, F.; Fernandez, M.; Sivilia, S.; Giardino, L.; Calza, L.; Norris, D.; Cicirello, H.; Casula, D.; Imbimbo, B.P. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment, a 12- week, double-blind, placebo-controlled study. Curr. Alzheimer Res., 2013, 10(7), 742-753.